

Data Sheet (14-Year Summary of Consolidated Financial Results of ASKA Pharmaceutical Holdings)

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012
Consolidated Financial Results (Millions of yen)														
Net sales	71,127	64,139	62,843	60,461	56,607	55,181	52,542	46,706	48,944	48,527	43,215	42,907	39,501	40,963
Cost of sales	36,982	32,803	32,178	31,876	30,255	29,798	28,525	27,814	30,059	29,614	26,072	25,717	22,431	23,047
Selling, general and administrative expenses	28,311	26,003	24,164	23,476	21,556	21,773	22,509	17,107	16,060	17,119	15,861 ^{*5}	15,767	16,353	16,847
Operating profit	5,834	5,331	6,500	5,108	4,795	3,609	1,507	1,782	2,824	1,793	1,283 ^{*6}	1,425	716	1,061
Ordinary profit	5,665	5,107	6,522	5,232	4,880	3,092	1,715	1,980	3,073	2,002	1,522	1,722	1,031	1,336
Profit attributable to owners of parent	5,424	5,101	7,545	4,238	4,290	2,713	649	1,744	2,388	2,944	701	1,193	495	1,114
R&D expenses	7,060	7,031	4,728	4,227	3,598	4,709	4,913	4,493	4,055	4,970	4,174	4,025	4,144	4,269
Capital expenditures (Property, plant and equipment and software (transfer basis))	2,702	2,700	1,540	1,256	657	765	2,040	2,994	1,443	772	2,279	2,285	2,047	937
Depreciation	2,917	2,247	2,662	3,127	2,885	3,305	3,669	2,491	2,324	2,447	1,969	1,709	2,355	2,353
Consolidated Financial Position (Millions of yen)														
Total assets	112,379	100,534	90,745	87,138	83,297	82,582	80,239	82,194	66,235	66,126	57,478	58,933	51,269	51,770
Net assets	76,819	69,195	61,930	54,533	48,892	44,510	41,573	43,456	42,559	39,511	35,961	36,577	33,941	33,350
Interest-bearing debt	11,434	10,903	9,485	12,623	14,046	16,395	16,419	16,468	2,950	3,700	5,708	1,366	1,557	1,782
Consolidated Cash Flows (Millions of yen)														
Cash flows from operating activities	6,303	2,485	1,486	3,351	2,842	6,541	-492	2,504	76	12,063	-1,349	5,710	2,616	3,869
Cash flows from investing activities	-5,752	-6,124	1,706	-1,126	6,743	-2,866	-2,927	-14,780	-3,348	-378	-6,776	-1,897	-2,301	-1,484
Cash flows from financing activities	-818	-2,956	-3,943	-1,820	-2,996	-455	-392	13,036	-1,142	-2,384	4,013	-557	-574	124
Cash and cash equivalents at end of period	10,126	10,603	16,738	17,505	17,103	10,514	7,294	11,107	10,346	14,761	5,462	9,574	6,318	6,578
Per-share Data (Yen)														
Earnings per share	191.12	179.95	266.51	150.08	151.22	95.72	22.96	61.81	84.80	105.39	25.15	42.89	17.85	40.27
Net assets per share	2,477.81	2,302.61	2,186.10	1,928.14	1,734.80	1,568.89	1,467.58	1,538.75	1,509.70	1,413.51	1,287.76	1,313.20	1,219.32	1,202.59
Dividends per share	60	55	40	16	15	14	17 ^{*4}	14	14	14	14	14	14	14
Financial Ratios (%)														
Cost of sales ratio	52.0	51.1	51.2	52.7	53.4	54.0	54.3	59.6	61.4	61.0	60.3	59.9	56.8	56.3
Selling, general and administrative expenses ratio	39.8	40.5	38.5	38.8	38.1	39.5	42.8	36.6	32.8	35.3	36.7	36.7	41.4	41.1
Operating profit margin	8.2	8.3	10.3	8.4	8.5	6.5	2.9	3.8	5.8	3.7	2.7	3.3	1.8	2.6
Equity ratio	62.6	65.0	68.2	62.6	58.7	53.9	51.8	52.9	64.3	59.8	62.6	62.1	66.1	64.4
Profit attributable to owners of parent / Equity (ROE)	5.0	5.3	7.3	6.1	5.9	3.8	2.1	2.7	4.6	3.2	2.6	3.1	2.0	2.6
Ordinary profit / Total assets (ROA)	8.0	8.0	13.0	8.2	8.8	6.3	1.5	4.1	5.8	7.8	1.9	3.4	1.5	3.4
Dividend payout ratio	31.4	30.6	15.0	10.7	5.3 ^{*3}	14.6	74.0	22.7	16.5	13.3	55.7	32.6	78.4	34.8
Non-financial Information														
Number of employees	1,611	1,632 ^{*1}	762	747	777	800	807	842	856	862	872	862	886	897
Number of issued shares (Thousands)	28,763	28,763 ^{*2}	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563

Notes:

Figures up to FY2020 are the figures announced by ASKA Pharmaceutical Co., Ltd.

*1. The addition of overseas operations has increased the number of employees by 857.

*2. 1,800 thousand shares decreased from the previous period due to the cancellation of treasury stock based on the resolution of the Board of Directors.

*3. Interim dividends are dividends from other capital surplus and are excluded from the dividend payout ratio.

*4. 100th anniversary commemorative dividend of ¥3 per share.

*5. Due to a change in presentation, Selling, general and administrative expenses for FY2015 were adjusted from ¥15,978 million to ¥15,861 million.

*6. Due to a change in presentation, Operating profit for FY2015 was adjusted from ¥1,166 million to ¥1,283 million